Small-molecule activators of NRF1 transcriptional activity prevent protein aggregation
Language English Country France Media print-electronic
Document type Journal Article
PubMed
39884031
DOI
10.1016/j.biopha.2025.117864
PII: S0753-3322(25)00058-7
Knihovny.cz E-resources
- Keywords
- DDI2, NGLY1, NRF1(NFE2L1), Proteasome, Protein aggregates, Small molecules,
- MeSH
- Transcriptional Activation drug effects MeSH
- Autophagy drug effects MeSH
- Caenorhabditis elegans * drug effects metabolism MeSH
- NF-E2-Related Factor 1 metabolism genetics MeSH
- Small Molecule Libraries pharmacology MeSH
- Humans MeSH
- Protein Aggregation, Pathological metabolism drug therapy MeSH
- Proteasome Endopeptidase Complex * metabolism MeSH
- Protein Aggregates * drug effects MeSH
- Animals MeSH
- Check Tag
- Humans MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Names of Substances
- NF-E2-Related Factor 1 MeSH
- Small Molecule Libraries MeSH
- Proteasome Endopeptidase Complex * MeSH
- Protein Aggregates * MeSH
Intracellular protein aggregation causes proteotoxic stress, underlying highly debilitating neurodegenerative disorders in parallel with decreased proteasome activity. Nevertheless, under such stress conditions, the expression of proteasome subunits is upregulated by Nuclear Factor Erythroid 2-related factor 1 (NRF1), a transcription factor that is encoded by NFE2L1. Activating the NRF1 pathway could accordingly delay the onset of neurodegenerative and other disorders with impaired cell proteostasis. Here, we present a series of small-molecule compounds based on bis(phenylmethylen)cycloalkanones and their heterocyclic analogues, identified via targeted library screening, that can induce NRF1-dependent downstream events, such as proteasome synthesis, heat shock response, and autophagy, in both model cell lines and Caenorhabditis elegans strains. These compounds increase proteasome activity and decrease the size and number of protein aggregates without causing any cellular stress or inhibiting the ubiquitin-proteasome system (UPS). Therefore, our compounds represent a new promising therapeutic approach for various protein conformational diseases, including the most debilitating neurodegenerative diseases.
References provided by Crossref.org
